This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.
Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.
We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.
202 patients with advanced grade 2 and grade 3 GEP-NETs will be randomized 1:1 by a computerized system. You are equally as likely to receive Targeted Radionuclide Therapy with n.c.a. lutetium-177-edotreotide as you are to receive a standard therapy with CAPTEM, everolimus or FOLFOX. Neither you nor your doctor will be able to choose which group you will be assigned to.
Please contact your study doctor to learn more about the inclusion and exclusion criteria and to check if you meet all requirements.
The average study duration for each patient (treatment and follow-up observation) will be approximately four years but may vary on an individual patient basis. The overall time in the study depends on multiple factors including the individual variability of treatment response and tumor progression.
The comparator treatments CAPTEM, everolimus or FOLFOX used in this study, are some of the current standard of care treatments. If you are allocated to the standard of care group, you will receive treatment with one of these drugs based on the prior benefit-risk assessment of your study doctor and according to local practice.
You are free to withdraw from the study at any time. If you withdraw, your regular medical care will continue unchanged.
COMPOSE will be conducted in approximately 40 specialist centers across 10 countries (Australia, France, Germany, India, Italy, Netherlands, Spain, Sweden, UK and USA).
If you are interested in taking part in the COMPOSE study, please contact your attending doctor or reach out to a participating study center nearby. You can find a full list of all participating centers below.